BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Criss CR, Makary MS. Salvage locoregional therapies for recurrent hepatocellular carcinoma. World J Gastroenterol 2023; 29(3): 413-424 [PMID: 36688022 DOI: 10.3748/wjg.v29.i3.413] [Reference Citation Analysis]
2 Liao X, Chen J, Luo D, Luo B, Huang W, Xie W. Prognostic value of long non-coding RNA MALAT1 in hepatocellular carcinoma: A study based on multi-omics analysis and RT-PCR validation. Pathol Oncol Res 2022;28:1610808. [PMID: 36685103 DOI: 10.3389/pore.2022.1610808] [Reference Citation Analysis]
3 Ma G, Xu X, Qi M, Zhang Y, Xu X. Radioactive polymeric microspheres as a novel embolic agent for radiological interventional therapy: A preliminary evaluation. Journal of Drug Delivery Science and Technology 2023;79:104061. [DOI: 10.1016/j.jddst.2022.104061] [Reference Citation Analysis]
4 Zhang Y, Chen H, Chen S, Duan Y, Cheng L, Gao J, Li W. Comparison of the Efficacy and Safety of Transarterial Chemoembolization Plus Microwave Ablation versus Surgical Resection in Patients with Solitary Large Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. J Hepatocell Carcinoma 2022;9:1309-21. [PMID: 36567798 DOI: 10.2147/JHC.S386264] [Reference Citation Analysis]
5 Reinders MTM, van Erpecum KJ, Smits MLJ, Braat AJAT, Bruijne J, Bruijnen R, Sprengers D, Man RA, Vegt E, IJzermans JNM, Moelker A, Lam MGEH. Safety and Efficacy of (166)Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study. J Nucl Med 2022;63:1891-8. [PMID: 35589409 DOI: 10.2967/jnumed.122.263823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhao H, Wu ZZ, Ren Q, Wu JJ, Wang Y, Feng JW, Rao M, Deng Q, Hu HY. Transcatheter Arterial Embolization Combined with Anti-vascular Agent Combretastatin A4 Phosphate Inhibits Growth and Vascularization of Liver Tumor in an Animal Model. Curr Med Sci 2022;42:1240-7. [PMID: 36462132 DOI: 10.1007/s11596-022-2617-1] [Reference Citation Analysis]
7 Krendl FJ, Messner F, Laimer G, Djanani A, Seeber A, Oberhuber G, Öfner D, Wolf D, Schneeberger S, Bale R, Margreiter C. Multidisciplinary Treatment of Liver Metastases from Intracranial SFTs/HPCs: A Report of Three Consecutive Cases. Curr Oncol 2022;29:8720-41. [PMID: 36421340 DOI: 10.3390/curroncol29110687] [Reference Citation Analysis]
8 Ji M, Zou H, Shu B, Liu G, Zhang B, Xu Z, Pang F, Cheng M, Sun Y, Du T, Sun C, Zhu C. Prognostic analysis of hepatocellular carcinoma with macrovascular invasion after liver resection and a successful case of conversion therapy. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.1042431] [Reference Citation Analysis]
9 Wang D, Liu J, Li T, Wang Y, Liu X, Bai Y, Wang C, Ju S, Huang S, Yang C, Zhou C, Zhang Y, Xiong B. A VEGFR targeting peptide-drug conjugate (PDC) suppresses tumor angiogenesis in a TACE model for hepatocellular carcinoma therapy. Cell Death Discov 2022;8:411. [PMID: 36202781 DOI: 10.1038/s41420-022-01198-9] [Reference Citation Analysis]
10 Xu Y, Fu S, Shang K, Zeng J, Mao Y. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib. Front Oncol 2022;12:958869. [DOI: 10.3389/fonc.2022.958869] [Reference Citation Analysis]
11 Ho S, Liu P, Hsu C, Huang Y, Liao J, Su C, Hou M, Huo T. Radiofrequency Ablation versus Transarterial Chemoembolization for Hepatocellular Carcinoma within Milan Criteria: Prognostic Role of Tumor Burden Score. Cancers 2022;14:4207. [DOI: 10.3390/cancers14174207] [Reference Citation Analysis]
12 Choi TW, Joo I, Kim H. Association of dysmorphic intratumoral vessel with high lung shunt fraction in patients with hepatocellular carcinoma. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-18697-5] [Reference Citation Analysis]
13 Chartampilas E, Rafailidis V, Georgopoulou V, Kalarakis G, Hatzidakis A, Prassopoulos P. Current Imaging Diagnosis of Hepatocellular Carcinoma. Cancers 2022;14:3997. [DOI: 10.3390/cancers14163997] [Reference Citation Analysis]
14 Li W, Pei Y, Wang Z, Liu J. Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Front Oncol 2022;12:930868. [DOI: 10.3389/fonc.2022.930868] [Reference Citation Analysis]
15 Gatti M, Maino C, Darvizeh F, Serafini A, Tricarico E, Guarneri A, Inchingolo R, Ippolito D, Ricardi U, Fonio P, Faletti R. Role of gadoxetic acid-enhanced liver magnetic resonance imaging in the evaluation of hepatocellular carcinoma after locoregional treatment. World J Gastroenterol 2022; 28(26): 3116-3131 [DOI: 10.3748/wjg.v28.i26.3116] [Reference Citation Analysis]
16 Pérez-López A, Martín-Sabroso C, Gómez-Lázaro L, Torres-Suárez AI, Aparicio-Blanco J. Embolization therapy with microspheres for the treatment of liver cancer: State-of-the-art of clinical translation. Acta Biomater 2022:S1742-7061(22)00412-3. [PMID: 35842035 DOI: 10.1016/j.actbio.2022.07.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Tharmaseelan H, Hertel A, Rennebaum S, Nörenberg D, Haselmann V, Schoenberg SO, Froelich MF. The Potential and Emerging Role of Quantitative Imaging Biomarkers for Cancer Characterization. Cancers (Basel) 2022;14:3349. [PMID: 35884409 DOI: 10.3390/cancers14143349] [Reference Citation Analysis]
18 De Re V, Rossetto A, Rosignoli A, Muraro E, Racanelli V, Tornesello ML, Zompicchiatti A, Uzzau A. Hepatocellular Carcinoma Intrinsic Cell Death Regulates Immune Response and Prognosis. Front Oncol 2022;12:897703. [DOI: 10.3389/fonc.2022.897703] [Reference Citation Analysis]
19 Huo TI, Liao JI, Ho SY. 3-Mercaptopyruvate sulfurtransferase in hepatocellular carcinoma: Is it an authentic clinical prognostic predictor? Liver Int 2022;42:1475. [PMID: 35460171 DOI: 10.1111/liv.15279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zane KE, Nagib PB, Jalil S, Mumtaz K, Makary MS. Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma. World J Hepatol 2022; 14(5): 885-895 [DOI: 10.4254/wjh.v14.i5.885] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Karahan Şen NP, Alataş Ö, Gülcü A, Özdoğan Ö, Derebek E, Çapa Kaya G. The role of volumetric and textural analysis of pretreatment 18F-fluorodeoxyglucose PET/computerized tomography images in predicting complete response to transarterial radioembolization in hepatocellular cancer. Nucl Med Commun 2022. [PMID: 35506284 DOI: 10.1097/MNM.0000000000001572] [Reference Citation Analysis]
22 Chai C, Zhou T, Zhu J, Tang Y, Xiong J, Min X, Qin Q, Li M, Zhao N, Wan C. Multiple Light-Activated Photodynamic Therapy of Tetraphenylethylene Derivative with AIE Characteristics for Hepatocellular Carcinoma via Dual-Organelles Targeting. Pharmaceutics 2022;14:459. [PMID: 35214196 DOI: 10.3390/pharmaceutics14020459] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
23 Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI. A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. Cancers (Basel) 2022;14:649. [PMID: 35158917 DOI: 10.3390/cancers14030649] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
24 Polikoff A, Wessner CE, Balasubramanya R, Dulka S, Liu JB, Machado P, Savsani E, Lyshchik A, Shaw CM, Eisenbrey JR. Imaging appearance of residual HCC following incomplete trans-arterial chemoembolization on contrast-enhanced imaging. Abdom Radiol (NY) 2022;47:152-60. [PMID: 34643782 DOI: 10.1007/s00261-021-03298-z] [Reference Citation Analysis]
25 Hare AE, Makary MS. Locoregional Therapies for Hepatocellular Carcinoma. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_42] [Reference Citation Analysis]
26 Yu MH, Tsai MC, Wang CC, Wu SW, Chang YJ, Wu CH, Wang CJ. Mulberry Leaf Polyphenol Extract and Rutin Induces Autophagy Regulated by p53 in Human Hepatoma HepG2 Cells. Pharmaceuticals (Basel) 2021;14:1310. [PMID: 34959709 DOI: 10.3390/ph14121310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Yanhan W, Lianfang L, Hao L, Yunfeng D, Nannan S, Fanfan L, Chengzhan Z, Meilong W, Chuandong S. Effect of Microvascular Invasion on the Prognosis in Hepatocellular Carcinoma and Analysis of Related Risk Factors: A Two-Center Study. Front Surg 2021;8:733343. [PMID: 34869551 DOI: 10.3389/fsurg.2021.733343] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons. World J Gastroenterol 2021; 27(43): 7462-7479 [PMID: 34887643 DOI: 10.3748/wjg.v27.i43.7462] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
29 Chen Q, Chen AZ, Jia G, Li J, Zheng C, Chen K. Molecular Imaging of Tumor Microenvironment to Assess the Effects of Locoregional Treatment for Hepatocellular Carcinoma. Hepatol Commun 2021. [PMID: 34738743 DOI: 10.1002/hep4.1850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
30 Yuan H, Lu H, Zeng J, Zhang Y, Shen L. Comparison of radiation doses between hepatic artery infusion chemotherapy and transarterial chemoembolization for liver cancer. Journal of Interventional Medicine 2021;4:184-9. [DOI: 10.1016/j.jimed.2021.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Granito A, Facciorusso A, Sacco R, Bartalena L, Mosconi C, Cea UV, Cappelli A, Antonino M, Modestino F, Brandi N, Tovoli F, Piscaglia F, Golfieri R, Renzulli M. TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. J Pers Med 2021;11:1041. [PMID: 34683182 DOI: 10.3390/jpm11101041] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
32 Zane KE, Cloyd JM, Mumtaz KS, Wadhwa V, Makary MS. Metastatic disease to the liver: Locoregional therapy strategies and outcomes. World J Clin Oncol 2021; 12(9): 725-745 [PMID: 34631439 DOI: 10.5306/wjco.v12.i9.725] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Fang S, Lai L, Zhu J, Zheng L, Xu Y, Chen W, Wu F, Wu X, Chen M, Weng Q, Ji J, Zhao Z, Tu J. A Radiomics Signature-Based Nomogram to Predict the Progression-Free Survival of Patients With Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation. Front Mol Biosci 2021;8:662366. [PMID: 34532340 DOI: 10.3389/fmolb.2021.662366] [Reference Citation Analysis]
34 Reizine E, Chalaye J, Mule S, Regnault H, Perrin C, Calderaro J, Laurent A, Amaddeo G, Kobeiter H, Tacher V, Itti E, Luciani A. Utility of Early Posttreatment PET/CT Evaluation Using FDG or 18F-FCH to Predict Response to 90Y Radioembolization in Patients With Hepatocellular Carcinoma. AJR Am J Roentgenol 2021. [PMID: 34494448 DOI: 10.2214/AJR.21.26485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Feng H, Yang C, Xu F, Zhao Y, Jin T, Wei Z, Wang D, Dai C. Therapeutic efficacy of microwave coagulation versus liver resection for hepatocellular carcinoma within the Milan criteria: A propensity score matching analysis. Eur J Surg Oncol 2021:S0748-7983(21)00725-3. [PMID: 34509336 DOI: 10.1016/j.ejso.2021.08.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Choi JW, Lee SY, Cho EJ, Jeong DI, Kim DD, Kim HC, Cho HJ. Gas generating microspheres for immediate release of Hsp90 inhibitor aiming at postembolization hypoxia in transarterial chemoembolization therapy of hepatocellular carcinoma. Int J Pharm 2021;607:120988. [PMID: 34389420 DOI: 10.1016/j.ijpharm.2021.120988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Mei J, Lin WP, Shi F, Wei W, Liang JB, Shi M, Zheng L, Li SH, Guo RP. Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy. Eur J Radiol 2021;142:109890. [PMID: 34375811 DOI: 10.1016/j.ejrad.2021.109890] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Xu H, Yu X, Hu J. The Risk Assessment and Clinical Research of Bile Duct Injury After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. Cancer Manag Res 2021;13:5039-52. [PMID: 34234549 DOI: 10.2147/CMAR.S303172] [Reference Citation Analysis]
39 Kim M, Lee Y, Yoon JS, Lee M, Kye SS, Kim SW, Cho Y. The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. Cancers (Basel) 2021;13:2301. [PMID: 34064988 DOI: 10.3390/cancers13102301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
40 Kutlu R, Karatoprak S. Radioembolization for Hepatocellular Carcinoma in Downstaging and Bridging for Liver Transplantation. J Gastrointest Cancer 2020;51:1157-64. [PMID: 32880041 DOI: 10.1007/s12029-020-00492-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
41 Ocker M, Mayr C, Kiesslich T, Stintzing S, Neureiter D. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers (Basel) 2021;13:1558. [PMID: 33805268 DOI: 10.3390/cancers13071558] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
42 Gundlach JP, Schmidt S, Bernsmeier A, Günther R, Kataev V, Trentmann J, Schäfer JP, Röcken C, Becker T, Braun F. Indication of Liver Transplantation for Hepatocellular Carcinoma Should Be Reconsidered in Case of Microvascular Invasion and Multilocular Tumor Occurrence. J Clin Med 2021;10:1155. [PMID: 33801887 DOI: 10.3390/jcm10061155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Ishihara A, Deguchi A, Arai H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Aino H, Matsukuma N, Matsugaki S, Ogata K, Yano Y, Ueno T, Kajiwara M, Itano S, Fukuizumi K, Kawano H, Noguchi K, Tanaka M, Yamaguchi T, Kuromatsu R, Kawaguchi A, Koga H, Torimura T, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan. Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. Cancers (Basel) 2021;13:646. [PMID: 33562793 DOI: 10.3390/cancers13040646] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
44 Moris D, Shaw BI, McElroy L, Barbas AS. Using Hepatocellular Carcinoma Tumor Burden Score to Stratify Prognosis after Liver Transplantation. Cancers (Basel) 2020;12:E3372. [PMID: 33202588 DOI: 10.3390/cancers12113372] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
45 Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12(10): 693-708 [PMID: 33200010 DOI: 10.4254/wjh.v12.i10.693] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]